Evidence-based Updates in Non-Hodgkin’s Lymphoma

By clicking the continue button above, I certify I have read the CME/CE information below.

Release Date: January 30, 2018
Expiration Date: January 30, 2019

Program Overview
Significant advances in treatment with novel agents for B-cell non-Hodgkin’s lymphoma (NHL) have improved patient outcomes and survival. However, many patients are at high-risk of relapse, meriting a precision approach to reduce the rate of recurrence and improve outcomes. The identification of molecular subtypes, the persistence of clinical challenges, and the anticipated emergence of clinical data necessitate a collaborative treatment approach to ensure individualized care for patients with diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

Target Audience
The primary audiences for this activity are:

  • Community-based oncologists and hematologists; drivers of evidence-based practice changes, treatments, and care planning across multiple tumor types
  • Oncology nurses, advanced practice nurse (APNs), registered nurses (RNs), and nurse practitioners (NPs); primary point persons for patient management and education
  • Oncology, health-system, and managed-care pharmacists; responsible for dispensing cancer therapies, ensuring appropriate use, and including new agents on Formularies
  • Oncology treatment-team members involved in managing patients with cancer and providing supportive services (e.g. financial advocates, nutrition plans, psychological assessment, genetic counseling, and navigation)


 Paul A. Hamlin, MD
 Chief of Medical Oncology
 MSKCC Basking Ridge
 Associate Member Physician on the Lymphoma Service
 Memorial Sloan-Kettering Cancer Center, Division of Hematologic Oncology
 Associate Professor of Medicine
 Weill Medical College of Cornell University Medical College
 New York, NY

Paul A. Hamlin, MD is Chief of Medical Oncology at MSKCC Basking Ridge, an Associate Member Physician on the Lymphoma Service at Memorial Sloan-Kettering Cancer Center in the Division of Hematologic Oncology, and an Associate Professor of Medicine at Weill Medical College of Cornell University Medical College in New York. He led the Innovation Lab for the Lymphoma service at MSKCC while Clinical Director (2011-2015).

Dr. Hamlin received his undergraduate degree from Duke University, then received his medical degree from the State University of New York Health Sciences Center at Brooklyn, graduating Magne Cum Laude and as a member of the AOA society. His postgraduate training included an internship and residency at New York University Hospital and a fellowship in medical oncology and hematology at Memorial Sloan-Kettering Cancer Center, where he served as Chief Fellow from 2001-2002. He is certified by the American Board of Internal Medicine and holds subspecialty certification in medical oncology.

Dr. Hamlin’s clinical area of expertise is the treatment of Hodgkin’s and non-Hodgkin’s lymphomas. He has specialized in the care of older patients with lymphoma, working on a multidisciplinary team to develop new treatment strategies and clinical trials specifically aimed at this patient population. His research interests include novel biologic and immunotherapeutic agents for the treatment of hematologic malignancies, with ongoing work in novel agents, small molecule inhibitors, monoclonal antibodies and antibody-drug conjugates. He is a member of several professional organizations including the American Society of Clinical Oncologists and the American Society of Hematology.

Educational Objectives
At the conclusion of this session, participants should be able to demonstrate the ability to:

  • Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
  • Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize survival in patients with lymphoma
  • Discuss current recommendations for diagnostic testing for lymphoma to facilitate treatment selection
  • Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of lymphoma with attention to cost/benefit and toxicity considerations
  • Evaluate resources to increase patient access and engagement

Physician Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM.  Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Pharmacist Accreditation

The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.


Pharmacist Designation
Total number of CE credits made available at this conference is 1.0 hours (0.10 CEUs).

UAN: 0418-9999-18-210-H04-P

A statement of credit will be issued only upon receipt of a completed activity evaluation.

This is an application-based activity.

For questions regarding CME/CE credit, the post-test, evaluation, please email contact@potomacme.org.

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Potomac Center for Medical Education, and Rockpointe Oncology.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.  Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Disclosure Information
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

Faculty Disclosures
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Paul A. Hamlin, MD: Consultant/Independent Contractor: Portola, Gilead, Celgene; Grant/Research Support: Seattle Genetics, Portola, Mol Template, Novartis, Janssen & Janssen; Honoraria: Celgene

Non-faculty Disclosures
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chad Williamson, MS, MBA, CMPP; Shawna Graves, PhD; Blair St. Amand; Judi Smelker-Mitchek, RN, MSN, MBA; Trace Hutchinson, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, MSN, FACEHP, RN, CHCP; Lindsay Scott, PT, DPT, ATC: Nothing to disclose

Gary I. Cohen, MD: Speaker’s Bureau: Genzyme, NantHealth; Shareholder: Celgene

Alex Ganetsky, PharmD: Honoraria/Advisory Board: Jazz; Speaker’s Bureau: Amgen, Incyte

FDA Disclosure
The content of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.

Instructions for Participants and Obtaining CME/CE Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/CE activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.  Participant is allowed to take the post-test multiple times.

Privacy Policy
Click here to view our privacy policy.

Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology


This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.